WO1998003672A1 - N-(r)-(2-hydroxy-2-pyridine-3-yl-ethyl)-2-(4-nitro-phenyl)-acetamide - Google Patents

N-(r)-(2-hydroxy-2-pyridine-3-yl-ethyl)-2-(4-nitro-phenyl)-acetamide Download PDF

Info

Publication number
WO1998003672A1
WO1998003672A1 PCT/US1997/012615 US9712615W WO9803672A1 WO 1998003672 A1 WO1998003672 A1 WO 1998003672A1 US 9712615 W US9712615 W US 9712615W WO 9803672 A1 WO9803672 A1 WO 9803672A1
Authority
WO
WIPO (PCT)
Prior art keywords
yeast
nutrient medium
monosodium glutamate
alcohol
chloride dihydrate
Prior art date
Application number
PCT/US1997/012615
Other languages
French (fr)
Other versions
WO1998003672A9 (en
Inventor
Michel M. Chartrain
John Y. L. Chung
Christopher Roberge
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9616805.9A external-priority patent/GB9616805D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to AU38046/97A priority Critical patent/AU3804697A/en
Publication of WO1998003672A1 publication Critical patent/WO1998003672A1/en
Publication of WO1998003672A9 publication Critical patent/WO1998003672A9/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10Nitrogen as only ring hetero atom
    • C12P17/12Nitrogen as only ring hetero atom containing a six-membered hetero ring

Definitions

  • This invention is concerned with a novel process for the synthesis of compound, I, a key intermediate in the synthesis of an important ⁇ 3-agonist, II, useful in the treatment of diabetes and obesity:
  • the ⁇ 3-agonist, II, and the key intermediate, I, produced by the novel process of this invention, are known compounds, being described in Patent Publication WO 95/29159. Processes for the preparation of Compounds I and II are also disclosed in WO 95/29159. However, the process to the intermediate I involves a chiral borane reduction of a pyridyl chloromethyl ketone hydrochloride followed by formation of the epoxide from the resulting chloromethyl pyridyl methanol and then opening of the epoxide with the appropriate amine.
  • novel process of this invention comprises incubating a compound of structural formula III
  • yeasts are capable of causing this asymmetric reduction with fairly high optical purity and good conversion of substrate to (R)-alcohol.
  • That yeast is identified as a Candida sorbophila, number MY 1833 in the Merck & Co., Inc. collection of yeasts. It has been deposited with ATCC on April 4, 1996 and received Accession No. 74362.
  • the nutrient medium employed in the novel process can be any medium known to be useful for growing yeast by those skilled in this art.
  • STAT1 medium consists of monosodium glutamate (20 g/L); MOPS (20 g/L); yeast extract (7 g/L); glucose (2 g/L); P-2000 (2 ml/L); Magnesium chloride hexahydrate (1 g/L); calcium chloride dihydrate (0.5 g/L); cupric chloride dihydrate (0.5 g/L); and potassium chloride (0.5 g/L).
  • the fermentation medium (STAT1, 16L) was added to the fermentation tank and sterilized for 35 min. at 123°C.
  • the pH of the broth was adjusted to 6.0-6.5 by the addition of HC1.
  • the other initial conditions of the fermenters were an agitation of 600 RPM, an airflow of 4L/min, a temperature of 30°C, and a pressure of 1 bar.
  • the dissolved oxygen in the fermenter was maintained above 30% of saturation through automated agitation control in the range between 600 and 700 RPM.
  • a substrate addition assembly was constructed by connecting a fermenter needle to approximately four feet of silicone rubber tubing (0.192" I.D. x 0.392" O.D.) attached to a 2-L bottle with a bottom spout, and to this 320 mL of pH 2 deionized water and a magnetic stir bar were added. The deionized water was acidified with phosphoric acid prior to adding it to the bottle. The assembly was autoclaved for 30 minutes at 121.5°C. After the equipment had cooled to room temperature, 40 g ketone substrate (Compound III) were measured in a weigh boat and added to the bottle using a metal spatula under a sterile hood.
  • Compound III Compound III
  • a volume of 1 liter of YNB medium [monosodium glutamate (93 g/L); citrate monohydrate (20 g/L); yeast nitrogen base w/o amino acids and ammonium sulfate (15 g/L); P-2000 (10 mL/L); cupric chloride dihydrate (15 mg/L)] was added to the bioreactor (2 liter) and sterilized for 30 min. at 123°C. Glucose that had been sterilized separately was added upon cooling to give a final concnetration of 7 g/L. A volume of 20 ml of the inoculum prepared as described above was then added to the bioreactor.
  • the microorganisms were cultivated under an agitation of 1200 RPM, a sparging of 0.5L/min of 90% oxygen", and a temperature of 34°C, until an optical density (OD) @ 600nm in the range of 15-25 and a glucose concentration of ⁇ 1 g/L were achieved.
  • the pH of the cultivation broth was adjusted to 8.0 and maintained at that value through the addition of sterile 5N NaOH and 5N H2SO4, ethanol in the amount of 13 ml and ketone substrate in the amount of 50 g were then charged to the tank.
  • glucose feeding was initiated at a rate of 1 g/(l*hr) from a 280 g/1 stock solution that had been autoclaved for 30 min at 121.5°C.
  • concentrations of ketone and alcohol in the broth were assayed by reverse phase HPLC and the e.e. of the alcohol was monitored by supercritical fluid HPLC.
  • the runs were terminated after approximately 7 days, when the amount of ketone in the fermenter as assayed by HPLC had reached ⁇ 1% of its initial value (See Example 1 for HPLC method). A final alcohol titer of 35 g/L with an ee of 98% was achieved under these conditions.

Abstract

Asymmetric bioreduction of a ketone substrate with yeast produces the corresponding (R)-alcohol of structure (I), a key intermediate in the synthesis of β3-agonist of structure (a).

Description

TITLE OF THE INVENTION
N-(R)-(2-HYDROXY-2-PYRIDINE-3-YL-ETHYL)-2-(4-NITRO-
PHENYL)-ACETAMIDE
CROSS REFERENCE TO RELATED APPLICATIONS
This application is based on, and claims priority from provisional application 60/022,055 filed on July 22, 1996.
SUMMARY OF THE INVENTION This invention is concerned with a novel process for the synthesis of compound, I, a key intermediate in the synthesis of an important β3-agonist, II, useful in the treatment of diabetes and obesity:
Figure imgf000003_0001
II
The novel process of this invention comprises the chiral bioreduction of compound III with a specific yeast to provide compound I.
Figure imgf000004_0001
BACKGROUND OF THE INVENTION
The β3-agonist, II, and the key intermediate, I, produced by the novel process of this invention, are known compounds, being described in Patent Publication WO 95/29159. Processes for the preparation of Compounds I and II are also disclosed in WO 95/29159. However, the process to the intermediate I involves a chiral borane reduction of a pyridyl chloromethyl ketone hydrochloride followed by formation of the epoxide from the resulting chloromethyl pyridyl methanol and then opening of the epoxide with the appropriate amine.
Figure imgf000004_0002
This synthesis suffered low overall yield due to competing reactions and the requirement of multiple silica chromatographies to obtain usable product. Specifically, the pyridyl chloromethyl ketone tends to polymerize during the reduction reaction, the resulting product mixture required tedious purification before it could be used; the epoxide opening reaction gave a plethora of products due to poor chemoselectivity; and the higher reactivity of the resulting secondary amines toward further alkylation. In the chiral borane reduction of the ketone, the best enantioselectivity obtained was only 89% enantiomeric excess (ee). This synthetic route clearly is not suitable for large scale preparation.
Now with the present invention there is provided a process for the synthesis of enantiomerically pure (ee>98%) (R)-alcohol, I, in high yield.
DETAILED DESCRIPTION OF THE INVENTION
The novel process of this invention comprises incubating a compound of structural formula III
Figure imgf000005_0001
with a yeast in a nutrient medium under controlled conditions to produce enantiomerically pure (ee>98%) (R)-alcohol of structural formula I.
Figure imgf000005_0002
Many yeasts are capable of causing this asymmetric reduction with fairly high optical purity and good conversion of substrate to (R)-alcohol. However, one has been identified as most useful for this novel process providing >97% conversion of substrate to the (R)-alcohol of >97% enantiomeric excess (ee). That yeast is identified as a Candida sorbophila, number MY 1833 in the Merck & Co., Inc. collection of yeasts. It has been deposited with ATCC on April 4, 1996 and received Accession No. 74362. The nutrient medium employed in the novel process can be any medium known to be useful for growing yeast by those skilled in this art. The media are composed of buffers such as 4- morpholinepropanesulfonic acid (MOPS), 2-(N- morpholino)ethanesulfonic acid (MES), or citrate; yeast extracts; carbohydrates such as glucose, sucrose, fructose, or glycerol; various inorganic salts to provide minerals such as magnesium, calcium, copper, potassium and sodium; and an antifoam agent such as Dow P-2000.
The fermentation conditions that should be controlled for optimum results are starting pH between 4 and 9; airflow of about 0.25-5 L/m; a temperature of about 25-35°C; and dissolved oxygen above about 30% of saturation.
EXAMPLE 1
Growth of Seed Train
The contents of one 1-mL frozen vial of Y 1833 {Candida sorbophila) in Saboraud Dextrose Broth were added to a 250-ml Erlenmeyer flask containing 50 ml of STAT1 medium described below that had been autoclaved for 30 minutes at 121°C. The culture was allowed to grow for 24 hours at 30°C on an orbital shaker at 200 RPM. From this flask, 10 mL of inoculum were added to a 2-L Erlenmeyer flask containing 500 ml of STAT1 medium that had been autoclaved for 30 minutes at 121°C. This culture was also allowed to grow for 24 hours at 30°C on an orbital shaker at 200 RPM. The contents of this flask were used as inoculum for a 16 L fermentation.
STAT1 medium consists of monosodium glutamate (20 g/L); MOPS (20 g/L); yeast extract (7 g/L); glucose (2 g/L); P-2000 (2 ml/L); Magnesium chloride hexahydrate (1 g/L); calcium chloride dihydrate (0.5 g/L); cupric chloride dihydrate (0.5 g/L); and potassium chloride (0.5 g/L).
Fermentations The fermentation medium (STAT1, 16L) was added to the fermentation tank and sterilized for 35 min. at 123°C. The pH of the broth was adjusted to 6.0-6.5 by the addition of HC1. In addtion to a 6.5 pH, the other initial conditions of the fermenters were an agitation of 600 RPM, an airflow of 4L/min, a temperature of 30°C, and a pressure of 1 bar. The dissolved oxygen in the fermenter was maintained above 30% of saturation through automated agitation control in the range between 600 and 700 RPM.
A substrate addition assembly was constructed by connecting a fermenter needle to approximately four feet of silicone rubber tubing (0.192" I.D. x 0.392" O.D.) attached to a 2-L bottle with a bottom spout, and to this 320 mL of pH 2 deionized water and a magnetic stir bar were added. The deionized water was acidified with phosphoric acid prior to adding it to the bottle. The assembly was autoclaved for 30 minutes at 121.5°C. After the equipment had cooled to room temperature, 40 g ketone substrate (Compound III) were measured in a weigh boat and added to the bottle using a metal spatula under a sterile hood. The weigh boat and spatula were then rinsed with 320 mL ethanol which was also added to the bottle under a fume hood. The assembly was placed on a stir plate that was used to agitate the mixture and create a suspension. The pressure in the tank was then reduced to 0.1 bar and the airflow was stopped while the suspension was pumped through the tubing and needle into the fermenter. Next, 320 mL deionized water that had been autoclaved for 30 minutes at 121°C were poured into the bottle and stirring and pumping were resumed to wash any remaining substrate into the tank. Finally, 500 mL inoculum were poured into the bottle, and again stirring and pumping were resumed. After the culture had been transferred to the fermenter, the tubing was clamped and the pressure and airflow of the tank were returned to their initial values. The concentrations of ketone and alcohol (Compound I) in broth samples were assayed by reverse phase HPLC (ODS-AQ column; [acetonitrile with 0.1% H3Pθ4]:[water with 1.77 g/1 NaH2P04 and 0.30 g/1 Na2HPθ4] mobile phase in a gradient from 10:90 to 80:20 over 20 min; 1.0 ml/min flow rate; 220 nm detection; and retention times of 12.6 min [alcohol] and 14.5 min [ketone]) and the e.e. of the alcohol was monitored by supercritical fluid HPLC (Chiralcel OD-H column; 300 bar column pressure; 35°C column temperature; modifier of 19% (v/v) methanol containing 20 mmol trichloroacetic acid; 1.0 ml/min flow rate; 260 nm detection; and retention times of 8.6 min [(R)-alcohol], 9.6 min [(S)-alcohol], and 13.7 min [ketone]). The runs were terminated after approximately 45 hours, when the amount of ketone in the fermenter as assayed by HPLC had reached <1% of its initial value and approximately 2.5 g/1 alcohol were in the tank.
Isolation
The fermentation batch was centrifuged to remove cells and fines.
Supernatant (170 mL) was extracted twice with 170 mL methyl ethyl ketone (MEK) saturated with water. The combined MEK extracts were concentrated to an aqueous slurry, sulfuric acid was added to pH2 and the slurry was extracted three times with isopropyl acetate/5% (v/v) isopropyl alcohol. The pH of the washed aqueous slurry was adjusted to 6.8 with 50% aqueous sodium hydroxide, following which fine crystalline solids gradually appeared.
The aqueous slurry was concentrated under vacuum to remove organic solvents. The room temperature aqueous slurry was filtered to collect the solid product and the filter cake was washed with cold water. Yield -70% (28 g); Purity -87%; ee 98.5%.
EXAMPLE 2
Seed Train The contents of one 1-mL frozen vial of Y 1833 (Candida sorbophila) preserved in Saboraud Dextrose Broth (Difco) and glycerol (20%, v/v) at -70°C were added to a 250-mL Erlenmeyer flask containing 50 mL of Sabouraud Dextrose Broth medium that had been autoclaved for 30 minutes at 121.5°C. The culture was allowed to grow for 24 hours at 34°C on an orbital shaker at 200 RPM. Biotransformation
A volume of 1 liter of YNB medium [monosodium glutamate (93 g/L); citrate monohydrate (20 g/L); yeast nitrogen base w/o amino acids and ammonium sulfate (15 g/L); P-2000 (10 mL/L); cupric chloride dihydrate (15 mg/L)] was added to the bioreactor (2 liter) and sterilized for 30 min. at 123°C. Glucose that had been sterilized separately was added upon cooling to give a final concnetration of 7 g/L. A volume of 20 ml of the inoculum prepared as described above was then added to the bioreactor. The microorganisms were cultivated under an agitation of 1200 RPM, a sparging of 0.5L/min of 90% oxygen", and a temperature of 34°C, until an optical density (OD) @ 600nm in the range of 15-25 and a glucose concentration of <1 g/L were achieved. At that time, the pH of the cultivation broth was adjusted to 8.0 and maintained at that value through the addition of sterile 5N NaOH and 5N H2SO4, ethanol in the amount of 13 ml and ketone substrate in the amount of 50 g were then charged to the tank. Immediately after these additions, glucose feeding was initiated at a rate of 1 g/(l*hr) from a 280 g/1 stock solution that had been autoclaved for 30 min at 121.5°C. The concentrations of ketone and alcohol in the broth were assayed by reverse phase HPLC and the e.e. of the alcohol was monitored by supercritical fluid HPLC. The runs were terminated after approximately 7 days, when the amount of ketone in the fermenter as assayed by HPLC had reached <1% of its initial value (See Example 1 for HPLC method). A final alcohol titer of 35 g/L with an ee of 98% was achieved under these conditions. Isolation
Isolation of the product is conducted in the same manner as described in Example 1. 8-

Claims

WHAT IS CLAIMED IS:
1. A process for the preparation of a compound of structural formula I:
Figure imgf000011_0001
which comprises incubating a substrate of structural formula III:
Figure imgf000011_0002
with a yeast in a nutrient medium.
2. The process of Claim 1 wherein the yeast is Candida .sorbophila, ATCC Accession No. 74362.
3. The process of Claim 2 wherein the nutrient medium comprises monosodium glutamate; a buffer; yeast extract; a carbohydrate; inorganic salts and an antifoam agent.
4. The process of Claim 3 wherein the initial pH is about 6.0-6.5; air flow of about 0.25-5 L/min; a temperature of about 25-35°C; and oxygen content above 30% of saturation.
5. The process of Claim 4 wherein the nutrient medium comprises monosodium glutamate (20 g/L); MOPS (20 g/L); yeast extract (7 g/L); glucose (2 g/L); P-2000 (2 ml/L); magnesium chloride hexahydrate (1 g-^L); calcium chloride dihydrate (0.5 g/L); cupric chloride dihydrate (0.5 g/L); and potassium chloride (0.5 g/L).
6. The process of Claim 3 wherein the medium is agitated at about 1200 RPM, with an air-flow of about 0.5 L/min of 90% oxygen, at a temperature of about 34°C.
7. The process of Claim 6 wherein the nutrient medium comprises monosodium glutamate (93 g/L); citrate monohydrate (20 g/L); yeast nitrogen base without amino acids, ammonium sulfate (15 g/L); P- 2000 (10 mL/L); and cupric chloride dihydrate (15 g/L).
PCT/US1997/012615 1996-07-22 1997-07-18 N-(r)-(2-hydroxy-2-pyridine-3-yl-ethyl)-2-(4-nitro-phenyl)-acetamide WO1998003672A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU38046/97A AU3804697A (en) 1996-07-22 1997-07-18 N-(r)-(2-hydroxy-2-pyridine-3-yl-ethyl)-2-(4-nitro-phenyl)-a cetamide

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2205596P 1996-07-22 1996-07-22
US60/022,055 1996-07-22
GBGB9616805.9A GB9616805D0 (en) 1996-08-09 1996-08-09 N-(R)-(2-hydroxy-2-pyridine-3-yl-ethyl)-2-(4-nitrophenyl)-acetamide
GB9616805.9 1996-08-09

Publications (2)

Publication Number Publication Date
WO1998003672A1 true WO1998003672A1 (en) 1998-01-29
WO1998003672A9 WO1998003672A9 (en) 1998-04-23

Family

ID=26309849

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/012615 WO1998003672A1 (en) 1996-07-22 1997-07-18 N-(r)-(2-hydroxy-2-pyridine-3-yl-ethyl)-2-(4-nitro-phenyl)-acetamide

Country Status (3)

Country Link
AR (1) AR007739A1 (en)
AU (1) AU3804697A (en)
WO (1) WO1998003672A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1153919A1 (en) * 1999-02-16 2001-11-14 Kaneka Corporation Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active beta3 agonist by the use of the same
EP1538215A1 (en) * 2002-06-28 2005-06-08 Takasago International Corporation Processes for producing lactone

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003568A1 (en) * 1986-11-13 1988-05-19 Schering Aktiengesellschaft Stereospecific keto-reduction of bicyclooctandione-carboxylic acid esters by microorganisms
EP0538693A2 (en) * 1991-10-23 1993-04-28 E.R. SQUIBB &amp; SONS, INC. Stereoselective preparation of halophenyl alcohols
WO1995029159A1 (en) * 1994-04-26 1995-11-02 Merck & Co., Inc. SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
WO1996002657A1 (en) * 1994-07-20 1996-02-01 Merck & Co., Inc. Microbial method

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003568A1 (en) * 1986-11-13 1988-05-19 Schering Aktiengesellschaft Stereospecific keto-reduction of bicyclooctandione-carboxylic acid esters by microorganisms
EP0538693A2 (en) * 1991-10-23 1993-04-28 E.R. SQUIBB &amp; SONS, INC. Stereoselective preparation of halophenyl alcohols
WO1995029159A1 (en) * 1994-04-26 1995-11-02 Merck & Co., Inc. SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
WO1996002657A1 (en) * 1994-07-20 1996-02-01 Merck & Co., Inc. Microbial method

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1153919A1 (en) * 1999-02-16 2001-11-14 Kaneka Corporation Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active beta3 agonist by the use of the same
EP1153919A4 (en) * 1999-02-16 2002-10-02 Kaneka Corp Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active beta3 agonist by the use of the same
US6515134B1 (en) 1999-02-16 2003-02-04 Kaneka Corporation Substituted acetylpridine derivatives and process for the preparation of intermediates for optically active beta-3 agonist by the use of the same
US6642387B2 (en) 1999-02-16 2003-11-04 Kaneka Corporation Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active β3 agonist by the use of the same
JP4676614B2 (en) * 1999-02-16 2011-04-27 株式会社カネカ Substituted acetylpyridine derivative and method for producing optically active beta-3 agonist intermediate using the same
EP1538215A1 (en) * 2002-06-28 2005-06-08 Takasago International Corporation Processes for producing lactone
EP1538215A4 (en) * 2002-06-28 2010-09-22 Takasago Perfumery Co Ltd Processes for producing lactone

Also Published As

Publication number Publication date
AU3804697A (en) 1998-02-10
AR007739A1 (en) 1999-11-10

Similar Documents

Publication Publication Date Title
CA2283376A1 (en) Synthesis of optically active phenylalanine analogs through microbial transformations
JPH11196890A (en) Production of optically active 3-quinuclidinol
JP2002535977A5 (en)
US5846791A (en) N-(R)-(2-hydroxy-2-pyridine-3-yl-ethyl)-2-(4-nitro-phenyl)-acetamide
WO1998003672A1 (en) N-(r)-(2-hydroxy-2-pyridine-3-yl-ethyl)-2-(4-nitro-phenyl)-acetamide
WO1998003672A9 (en) N-(r)-(2-hydroxy-2-pyridine-3-yl-ethyl)-2-(4-nitro-phenyl)-acetamide
CA2116003C (en) Arylalkanoic acid resolution
KR101579766B1 (en) Method for preparing cyclic lipopeptide compound
CA1206435A (en) Method for the production of l-phenylalanine through the reuse of phenylalanine ammonia lyase
FI77893C (en) FRAMEWORK FOR FRAMSTAELLNING AV INDANYLDERIVAT.
US6455730B1 (en) Preparation of dicarboxylic acid monoesters from cyanocarboxylic acid esters
JP2002281993A (en) Method for producing shikimic acid
ES2332648T3 (en) PROCEDURE FOR PREPARATION OF DERIVATIVES OF L-PHENYLALANINE BY MICROORGANISMS.
KR100345847B1 (en) Process for preparing cefazolin by using immobilized enzyme
JPH0639480B2 (en) New macrolide antibiotic M119
JP2981250B2 (en) Method for producing D-pantothenonitrile
JPS6125359B2 (en)
JP2828729B2 (en) Method for producing optically active 1,3-butanediol
JP3659123B2 (en) Method for optical resolution of 4-halogeno-3-alkanoyloxybutyronitrile
CN111424061A (en) Rhodococcus ruber and method for producing nicotinamide by using same
US20040106117A1 (en) Production process of l-phenylanine derivatives by microorganisms
JPH1014589A (en) Candida lipolytica hna-110 strain and production of 2,6-dihydroxy-3-naphthoic acid
JP2003024048A (en) New microorganism and method for producing pyruvic acid by the microorganism
JPH0366297B2 (en)
JPH0622776A (en) Production of n-long-chain acylamino acid by fermentation method

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGE 8, DESCRIPTION, AND PAGES 9 AND 10, CLAIMS, REPLACED BY NEW PAGES 8 AND 9, CLAIMS; DUE TO LATETRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: CA

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998507102

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase